Actuate Therapeutics, Inc. entered a material agreement; disclosed a material event
SEC 8-KRead source ↗
Actuate Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders1 buying, 1 selling1 purchase and 1 sale by directors and officers, last 12 monthsInsider trades
- Funds34 adding, 34 cuttingOf 5 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Actuate Therapeutics, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 118% and a beta of 1.7 against the S&P 500.
- Heavily shorted. 17.7% of the shares available to trade are sold short (5.8 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results
- Earnings per share
- -$0.20 against an average estimate of -$0.20: missed by 1.3%
- Next report
- November 12, 2026; average EPS estimate -$0.17
Price chart
- 1 day+2.1%
- 1 week-35.2%
- 1 month-58.2%
- This year-94.4%
- 1 year-94.9%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-0.89
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Agreement
No model value for Actuate Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Actuate Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.97 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no positive revenue in the latest twelve months |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Actuate Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.17 (range −$0.21 to −$0.15) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.73 | +31% | — | 0% |
| Next | −$0.66 | +9% | — | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −6.4% on 90 days ago. In the last 30 days, 1 analyst raised Actuate Therapeutics, Inc.'s forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.78 | −$0.85 |
| 60 days ago | −$0.78 | −$0.85 |
| 30 days ago | −$0.78 | −$0.85 |
| 7 days ago | −$0.67 | −$0.72 |
| Now | −$0.73 | −$0.66 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.20 | −$0.20 | −1.3% |
| Mar 2026 | −$0.21 | −$0.24 | −15.7% |
| Dec 2025 | −$0.24 | −$0.18 | +26.5% |
| Sept 2025 | −$0.28 | −$0.25 | +9.9% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 17.7% of tradable shares
- Days to cover
- 5.84 at average volume
- Short interest, 1 month
- +70% to October 15, 2026
- Held by institutions
- 25% of shares
- Held by insiders
- 7.0% of shares
- Employees
- 12 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2025 | 2026 to date |
|---|---|---|
| Return | ||
| ACTU | −23% | −94% |
| Industry peers (median) | −5% | −26% |
| S&P 500 | +18% | +11% |
| Months that ended higher | ||
| ACTU | 50% | 27% |
| S&P 500 | 75% | 46% |
| Largest fall from a high during the year | ||
| ACTU | −52% | −95% |
| S&P 500 | −19% | −9% |
Worst fall since August 13, 2024: 97% from May 30, 2025 to October 30, 2026. Getting back needed a 3452% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.34 – $7.63
- From 52-week high
- −95.5%
- vs 50-day average
- −61.2%
- vs 200-day average
- −84.0%
- Volatility (1 year)
- 118%
- Beta vs S&P 500
- 1.72
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $20.7M
- Institutions reporting
- 64
- Shares held vs prior quarter
- ▼ 2.5%
- Positions opened / closed
- 16 / 14
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Bios Capital Management, LP | $15.4M | 10.0M | 74.4% | 0.0% |
| Voss Capital, LP | $2.6M | 1.7M | 12.8% | 0.0% |
| Vanguard Capital Management LLC | $601,952 | 393K | 2.9% | ▼ 1.8% |
| AQR Capital Management LLC | $195,064 | 127K | 0.9% | ▲ 370.3% |
| Geode Capital Management, LLC | $172,207 | 113K | 0.8% | ▼ 50.7% |
| Texas Capital Bank Wealth Management Services Inc | $156,997 | 103K | 0.8% | ▲ 8.5% |
| Palogic Value Management, L.P. | $153,000 | 100K | 0.7% | 0.0% |
| Millennium Management LLC | $147,927 | 97K | 0.7% | New |
| Blackrock, Inc. | $137,754 | 90K | 0.7% | ▼ 78.9% |
| Abs Investment Management LLC | $111,975 | 73K | 0.5% | — |
| Abs Direct Equity Fund LLC | $111,975 | 73K | 0.5% | ▲ 46.4% |
| Vanguard Fiduciary Trust Co | $83,380 | 54K | 0.4% | ▼ 12.9% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Actuate Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $50,000 1 trade by 1 insider, last 12 months Insider sales History → $1.6M 1 trade by 1 insider · 0% under pre-set plans
Net ▼ $1.6M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Schmitt Daniel M President, CEO and Director | October 28, 2026 | Buy | 140,844 | $0.35 | $50,000 |
| Thomson Todd S Director | January 5, 2026 | Sell | 280,000 | $5.80 | $1.6M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
- 8-K Current report
- 8-K Current report
- S-1 REGISTRATION STATEMENT
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Actuate Therapeutics, Inc. in brief
- What does Actuate Therapeutics, Inc. do?
- Actuate Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Actuate Therapeutics, Inc.'s stock ticker?
- Actuate Therapeutics, Inc. trades under the ticker ACTU on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Actuate Therapeutics, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Bios Capital Management, LP, Voss Capital, LP and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Actuate Therapeutics, Inc. stock?
- Over the last 12 months, Actuate Therapeutics, Inc.'s directors and officers reported 1 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
- When is Actuate Therapeutics, Inc.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Actuate Therapeutics, Inc. announces its own schedule.
Follow research on Actuate Therapeutics, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.